All data are based on the daily closing price as of June 6, 2025
p
PharmaEssentia
6446.TW
16.97 USD
-0.72
-4.07%
Overview
Last close
16.97 usd
Market cap
5.79B usd
52 week high
23.57 usd
52 week low
8.76 usd
Target price
23.41 usd
Valuation
P/E
45.3299
Forward P/E
N/A
Price/Sales
14.9069
Price/Book Value
6.0437
Enterprise Value
5.18B usd
EV/Revenue
13.6646
EV/EBITDA
34.2875
Key financials
Revenue TTM
378.97M usd
Gross Profit TTM
333.96M usd
EBITDA TTM
98.19M usd
Earnings per Share
0.39 usd
Dividend
N/A usd
Total assets
867.04M usd
Net debt
-583.77M usd
About
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.